Skip to content
November 22, 2026
  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram
Business Quest

Business Quest

Focus on Enterprises and Innovation

  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
  • HOME
  • BUSINESS
    • BANKING
    • FINANCE
    • INSURANCE
    • SME’s
    • REAL ESTATES
    • INVESTMENTS
    • ENERGY
    • RETAIL
  • CAPTAINS OF INDUSTRY
  • INNOVATION & ENTERPRISES
  • WOMEN & POWER
  • TECHNOLOGY
  • OPINION
    • Corporate News from Media OutReach Newswire
Watch Online
  • Home
  • Corporate News from Media OutReach Newswire
  • Sapu Nano Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
  • Corporate News from Media OutReach Newswire

Sapu Nano Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway

Media OutReach Newswire July 9, 2026
SAN DIEGO, US – Media OutReach Newswire – 9 July 2026 – Sapu Nano (US) LLC, a clinical-stage biotechnology company developing the proprietary Deciparticle™ nanomedicine platform, today announced that the independent Safety Review Committee (SRC) has completed its review of the initial safety cohort in the Company’s ongoing SP-03-B101 Phase 1b clinical trial evaluating Sapu003, an investigational intravenous formulation of everolimus.

Following completion of the protocol-defined 28-day dose-limiting toxicity (DLT) evaluation period for the initial three-patient cohort, the SRC concluded that no dose-limiting toxicities were observed and recommended advancing the study to the next planned dose level. Enrollment into the second dose cohort has commenced.

SP-03-B101 is an open-label, multicenter, Bayesian Optimal Interval (BOIN) dose-escalation study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of weekly intravenous Sapu003 in patients with advanced mTOR-sensitive solid tumors. The study is registered on ClinicalTrials.gov (Identifier: NCT07369505).

Following successful completion of the initial safety cohort, the Company has initiated expansion of the SP-03-B101 clinical program into Europe, broadening patient access and supporting the global clinical development strategy for Sapu003.

“The independent Safety Review Committee’s recommendation to advance to the next dose level provides important clinical validation of the Sapu003 program,” said Dr. Vuong Trieu, Chief Executive Officer of Sapu Nano. “Combined with the expansion of SP-03-B101 into Europe, these milestones position Sapu003 for accelerated clinical development while broadening access for patients with advanced mTOR-sensitive solid tumors.”

Peer-Reviewed Publication Supports Clinical Development

The clinical milestone follows the Company’s recent peer-reviewed publication describing the scientific foundation of Sapu003 and the Deciparticle™ platform:

Min SH, Forero K, Putnam W, Anderson J, Hoff R, Lopp J, Trieu V, Ho K, Lee C. Intravenous Everolimus Formulation (Sapu003) for Clinical Trials. International Journal of Molecular Sciences. 2026;27(13):5775. doi: 10.3390/ijms27135775.

The publication provides the first comprehensive description of the Deciparticle™ platform and describes a stable intravenous everolimus nanoparticle formulation with a mean particle size below 20 nanometers, identification of mPEG-Chol as the optimal carrier, a scalable cGMP manufacturing process suitable for clinical production, and potent preclinical antitumor activity.

Clinical Trial Information

Study Title: SP-03-B101: A Phase 1b Study of Sapu003 (Intravenous Everolimus) in Patients with Advanced mTOR-Sensitive Solid Tumors

ClinicalTrials.gov Identifier: NCT07369505

About Sapu003

Sapu003 is an investigational intravenous formulation of everolimus developed using Sapu Nano’s proprietary Deciparticle™ nanoparticle platform. Sapu003 is designed to overcome the formulation limitations associated with oral everolimus by enabling intravenous administration with a scalable cGMP manufacturing process. The program is currently being evaluated in the Phase 1b SP-03-B101 clinical trial in patients with advanced mTOR-sensitive solid tumors.

About Sapu Nano’s Deciparticle™

Sapu Nano’s Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.

Hashtag: #SapuNano

The issuer is solely responsible for the content of this announcement.

About Sapu Nano

Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.

Post navigation

Previous Thailand’s BOI Approves $688 Million Nestlé Investment for AI-Driven Regional Coffee Hub
Next Dusit International expands ASAI Hotels pipeline in Thailand with new lifestyle hotels in Hat Yai and Phuket

Related Stories

Yeebo Announces Interim Results for FY26/27 Revenue Increases by 45.5% to HK$806.7 Million Profit Attributable to Owners Surges 87.6% to HK$2,284.7 Million
  • Corporate News from Media OutReach Newswire

Yeebo Announces Interim Results for FY26/27 Revenue Increases by 45.5% to HK$806.7 Million Profit Attributable to Owners Surges 87.6% to HK$2,284.7 Million

November 20, 2026
Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chinese Mainland
  • Corporate News from Media OutReach Newswire

Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chinese Mainland

November 20, 2026
A New Grassland Hub Connecting to the World: Hohhot Shengle International Airport Set to Open
  • Corporate News from Media OutReach Newswire

A New Grassland Hub Connecting to the World: Hohhot Shengle International Airport Set to Open

November 20, 2026

Recent Comments

  • TikTok Removes over 750,000 Videos for Platform Violations on TikTok removes over 800,000 Videos for Laws violations Q12026
  • ESAK,NCBA Partner Advances Investment and financing in Energy on NCBA Commits Sh12 Million to Sponsor KMI Motorshow 2026
  • World Toilet Day:Sanitation an affordable investment for households on KWFT appoints Rose Muyanga as the Managing Director
  • How the Pacemaker Changed the Way to Treat Human Heart on Health Tips:Breast Cancer is no longer a Disease for the Elderly
  • KCB Wraps up Common Cents comedy Tour in Nairobi on KCB Bank Kenya eyes Under-18 Children with a Savings Account

Connect with Us

  • WhatsApp
  • Facebook
  • Twitter
  • Youtube
  • LinkedIn
  • Instagram

You may have missed

TikTok Removes over 750,000 Videos for Platform Violations
  • digital skills
  • Entertainment
  • INNOVATION & ENTERPRISES
  • Laws
  • Tech
  • TikTok
  • TikToK for Business

TikTok Removes over 750,000 Videos for Platform Violations

November 21, 2026
Yeebo Announces Interim Results for FY26/27 Revenue Increases by 45.5% to HK$806.7 Million Profit Attributable to Owners Surges 87.6% to HK$2,284.7 Million
  • Corporate News from Media OutReach Newswire

Yeebo Announces Interim Results for FY26/27 Revenue Increases by 45.5% to HK$806.7 Million Profit Attributable to Owners Surges 87.6% to HK$2,284.7 Million

November 20, 2026
Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chinese Mainland
  • Corporate News from Media OutReach Newswire

Sighting Dragons in the Field: An Exhibition of Dinosaur Fossils from Port Island and the Chinese Mainland

November 20, 2026
A New Grassland Hub Connecting to the World: Hohhot Shengle International Airport Set to Open
  • Corporate News from Media OutReach Newswire

A New Grassland Hub Connecting to the World: Hohhot Shengle International Airport Set to Open

November 20, 2026

About Us

Our main focus is on quality Business news content that is verified and ready to be consumed by our users.

Our partners and readers alike are our heartbeat we value them in all that we do.

We offer an alternative as a mouthpiece to SMEs, entrepreneurs, and professionals on their daily long-term plans and milestone as well exchange the business ideas and success stories and to provide advertising services tailor-made to the needs and expectations of their products and services.

Join us in this endeavor to give you fast accurate and precise information as they develop.

 

 

Copyright ©2026 All rights reserved. | Businessquest by Geckoworks Ke_.